Canopy Growth Corporation

Cellares Revolutionizes Cell Therapy Manufacturing with Automated Platform for Autoimmune and Cancer Treatments

2 months ago

• Cellares has successfully completed a Technology Adoption Program with Cabaletta Bio, demonstrating their Cell Shuttle platform can automate and scale manufacturing of rese-cel, a CAR-T therapy for autoimmune diseases including myositis, scleroderma, and lupus nephritis. • The company has also formed a strategic partnership with the University of Wisconsin School of Medicine and Public Health to automate production of a CRISPR-edited GD2 CAR-T therapy for solid tumors, addressing manufacturing bottlenecks in clinical development. • Cellares' Integrated Development and Manufacturing Organization (IDMO) Smart Factories in the US, Europe, and Japan aim to reduce manufacturing costs by up to 50% while increasing production capacity tenfold compared to conventional CDMOs.

KIYATEC Secures CAP Accreditation and NY State Approval for Revolutionary 3D Cancer Diagnostic Platform

3 months ago

• KIYATEC's laboratory has received prestigious College of American Pathologists (CAP) accreditation and New York State approval for its innovative 3D Predict cancer diagnostic test, validating its quality standards and clinical utility. • The company's proprietary 3D cell culture platform represents a breakthrough in functional precision oncology, offering the first evidence-based correlation between therapeutic response predictions and actual patient outcomes. • The 3D Predict platform brings new hope for high-grade glioma patients, including those with glioblastoma, by providing oncologists with patient-specific treatment response predictions to guide therapy decisions.

Canopy Growth Expands German Medical Cannabis Portfolio with Tweed Brand Launch

3 months ago

• Canopy Growth has introduced its established Tweed brand to the German medical cannabis market, launching four new EU-cultivated strains through a partnership with Portuguese cultivator Gro-Vida. • The expansion includes high-THC genetics with sativa-dominant Jack Herer, indica-prominent Balanced Caramel and Wappa, and hybrid Gelato 33 strains, following December's Glitter Bomb launch with Cansativa. • This strategic move strengthens Canopy Growth's position in the German medical cannabis sector by ensuring consistent supply through EU-GMP facilities and partnerships with European cultivators.

Octavian Therapeutics Emerges with New Brand and £10M Fundraising Plan for Neuropathic Pain Drug Development

3 months ago

• OCT Holdings rebrands as Octavian Therapeutics, appointing Lord Mott as new Chair and establishing U.S. presence through Delaware-based subsidiary to accelerate growth in North America. • Company's lead candidate CB2 agonist successfully completed Phase 1 trials for diabetic peripheral neuropathy, with planned expansion into chemotherapy-induced neuropathy and IBS treatment. • Strategic £10M fundraising initiative launching March 2025 to advance clinical trials, facilitate IND filing, and expand AI-driven drug discovery platform.